These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25582746)

  • 21. Predictive factors for residual disease in re-excision specimens after breast-conserving surgery.
    Atalay C; Irkkan C
    Breast J; 2012; 18(4):339-44. PubMed ID: 22616572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Casting-type calcifications with invasion and high-grade ductal carcinoma in situ: a more aggressive disease?
    Zunzunegui RG; Chung MA; Oruwari J; Golding D; Marchant DJ; Cady B
    Arch Surg; 2003 May; 138(5):537-40. PubMed ID: 12742959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphovascular infiltration in the tumor bed is a useful marker of biological behavior in breast cancer.
    Panagiotopoulos N; Lagoudianakis E; Pappas A; Filis K; Salemis N; Manouras A; Kontzoglou K; Zografos G
    J BUON; 2016; 21(5):1082-1089. PubMed ID: 27837608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High incidence of triple-negative tumors in sub-saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital.
    Ly M; Antoine M; Dembélé AK; Levy P; Rodenas A; Touré BA; Badiaga Y; Dembélé BK; Bagayogo DC; Diallo YL; Koné AA; Callard P; Bernaudin JF; Diallo DA
    Oncology; 2012; 83(5):257-63. PubMed ID: 22964749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there 'progression through grade' in ductal invasive breast cancer?
    Schymik B; Buerger H; Krämer A; Voss U; van der Groep P; Meinerz W; van Diest PJ; Korsching E
    Breast Cancer Res Treat; 2012 Oct; 135(3):693-703. PubMed ID: 22886478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple-negative breast cancer: histological subtypes and immunohistochemical and clinicopathological features.
    Ishikawa Y; Horiguchi J; Toya H; Nakajima H; Hayashi M; Tagaya N; Takeyoshi I; Oyama T
    Cancer Sci; 2011 Mar; 102(3):656-62. PubMed ID: 21214677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
    von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
    J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic accuracy and prognostic value of core biopsy in the management of breast cancer: a series of 542 patients.
    Richter-Ehrenstein C; Müller S; Noske A; Schneider A
    Int J Surg Pathol; 2009 Aug; 17(4):323-6. PubMed ID: 19029173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
    Tas F
    Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.
    Wong H; Lau S; Cheung P; Wong TT; Parker A; Yau T; Epstein RJ
    BMC Cancer; 2014 Nov; 14():826. PubMed ID: 25385074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast.
    Aguiar FN; Mendes HN; Bacchi CE; Carvalho FM
    Rev Bras Ginecol Obstet; 2013 Mar; 35(3):97-102. PubMed ID: 23538467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer.
    Bar Y; Bar K; Feldman D; Dror JB; Shahoha M; Lerner S; Shachar SS; Weiss-Meilik A; Dershowitz N; Wolf I; Sonnenblick A
    Breast; 2024 Oct; 77():103777. PubMed ID: 39038425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.